Corporate

Pryor Cashman represented Maxim Group in their capacity as sales agent in connection with an at-the-market offering of up to $20,000,000 of common stock of Nemaura Medical, Inc. that launched on October 19, 2018.

Nemaura Medical (NMRD) is a medical technology company developing sugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) designed to help people with diabetes and pre-diabetics to better manage their glucose levels. SugarBEAT® consists of a daily disposable adhesive skin-patch connected to a rechargeable transmitter, with an app displaying glucose readings at five-minute intervals for periods of up to 24 hours.

Corporate Partner Ali Panjwani advised Maxim Group on the transaction.